首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5512篇
  免费   584篇
  国内免费   8篇
耳鼻咽喉   63篇
儿科学   183篇
妇产科学   113篇
基础医学   559篇
口腔科学   66篇
临床医学   690篇
内科学   815篇
皮肤病学   120篇
神经病学   544篇
特种医学   156篇
外科学   585篇
综合类   54篇
一般理论   7篇
预防医学   653篇
眼科学   40篇
药学   322篇
中国医学   3篇
肿瘤学   1131篇
  2023年   37篇
  2022年   67篇
  2021年   152篇
  2020年   98篇
  2019年   139篇
  2018年   204篇
  2017年   162篇
  2016年   163篇
  2015年   192篇
  2014年   271篇
  2013年   342篇
  2012年   498篇
  2011年   531篇
  2010年   257篇
  2009年   240篇
  2008年   324篇
  2007年   326篇
  2006年   326篇
  2005年   272篇
  2004年   282篇
  2003年   218篇
  2002年   190篇
  2001年   54篇
  2000年   78篇
  1999年   56篇
  1998年   47篇
  1997年   38篇
  1996年   25篇
  1995年   28篇
  1994年   18篇
  1993年   25篇
  1992年   40篇
  1991年   36篇
  1990年   33篇
  1989年   35篇
  1988年   31篇
  1987年   25篇
  1986年   25篇
  1985年   19篇
  1984年   21篇
  1983年   17篇
  1982年   10篇
  1981年   12篇
  1980年   13篇
  1979年   11篇
  1977年   13篇
  1976年   9篇
  1975年   16篇
  1974年   8篇
  1973年   16篇
排序方式: 共有6104条查询结果,搜索用时 328 毫秒
1.
2.
3.

Introduction

In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.

Methods

Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.

Results

Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.

Conclusions

These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population.  相似文献   
4.
Infantile hemangiomas (IHs) are the most common benign tumor of infancy, characterized by a natural history of early proliferation in the first months of life to eventual involution during childhood, often with residual fibrofatty tissue. Once involution has been achieved, IHs do not typically recur. We present two cases of exogenous growth hormone therapy resulting in the recurrence of IHs in late childhood, supported by radiological, immunohistochemical, in vitro, and in vivo evidence.  相似文献   
5.
6.
7.
8.
9.
OBJECTIVE: This article 1) provides an overview of formal Health Sciences Teaching Scholars Programs as presented in medical education literature and 2) presents information about an innovative multidiscipline Teaching Scholars Program. METHOD: Health Sciences Teaching Scholars Programs and similar programs were reviewed in the medical education literature to identify similar and dissimilar characteristics. The WVU Teaching Scholars Program highlighted in this article is presented with a discussion of goals, objectives, target audiences, course length, session frequency, program topics, learning methods, and assessments of the programs. A summary of the WVU Teaching Scholars Program and two Teaching Scholars Programs at McGill University and the University of Toronto were presented at the Association for American Medical Colleges (AAMC) annual meeting in 2006 for input from the general medical education audience. RESULTS: Comparisons of Health Sciences Teaching Scholars Programs reveal that successful programs are uniquely shaped by their educational environments. Scholars report that they value learning new teaching methods and improving their educational careers. CONCLUSION: Teaching Scholars Programs are valuable for the development of enhancing both teaching and scholarship in Health Sciences Programs and must adapt to the uniqueness of their respective educational environments and must continue to nurture scholars beyond graduation.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号